Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference
Fusion Pharmaceuticals (NASDAQ: FUSN), a clinical-stage oncology company, announced its participation in a panel titled "Novel Oncology Targets" at the 43rd Annual Cowen Healthcare Conference, scheduled for March 7, 2023, at 9:10 a.m. ET. CEO John Valliant, Ph.D. will represent the company during this event. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-presentation. Fusion focuses on next-generation radiopharmaceuticals, including its clinical pipeline with products targeting prostate cancer and other malignancies. The company also collaborates with AstraZeneca and Merck for novel therapies.
- None.
- None.
A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 30 days following their respective presentation dates.
Contact:
Senior Director of Investor Relations & Corporate Communications
(617) 967-0207
cray@fusionpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-43rd-annual-cowen-healthcare-conference-301761582.html
SOURCE
FAQ
When will Fusion Pharmaceuticals present at the Cowen Healthcare Conference?
Who will represent Fusion Pharmaceuticals at the conference?
How can I watch the Fusion Pharmaceuticals presentation?
What is the focus of Fusion Pharmaceuticals?